Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

P3 Health Partners (PIIIW) EBITDA (2020 - 2025)

P3 Health Partners' EBITDA history spans 6 years, with the latest figure at -$153.4 million for Q4 2025.

  • For Q4 2025, EBITDA fell 11.29% year-over-year to -$153.4 million; the TTM value through Dec 2025 reached -$268.1 million, up 15.76%, while the annual FY2025 figure was -$268.1 million, 15.76% up from the prior year.
  • EBITDA reached -$153.4 million in Q4 2025 per PIIIW's latest filing, down from -$43.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $36.3 million in Q4 2021 to a low of -$911.6 million in Q2 2022.
  • Average EBITDA over 5 years is -$116.1 million, with a median of -$43.5 million recorded in 2024.
  • Peak YoY movement for EBITDA: crashed 13853.67% in 2022, then soared 97.76% in 2023.
  • A 5-year view of EBITDA shows it stood at $36.3 million in 2021, then plummeted by 1574.85% to -$535.9 million in 2022, then skyrocketed by 88.1% to -$63.8 million in 2023, then crashed by 116.13% to -$137.8 million in 2024, then dropped by 11.29% to -$153.4 million in 2025.
  • Per Business Quant, the three most recent readings for PIIIW's EBITDA are -$153.4 million (Q4 2025), -$43.7 million (Q3 2025), and -$33.5 million (Q2 2025).